FDA Moves to Restrict Compounding GLP-1 Ingredients

The Food and Drug Administration said Friday it intends to restrict access to GLP-1 drug ingredients used in nonapproved compounded weight-loss products and that Hims & Hers Health Inc. could face federal enforcement, a move the agency said is aimed at curbing mass-marketed …[#item_full_content]